The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry

James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer, Eur Urol, 79, 263, 10.1016/j.eururo.2020.09.046 Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835 Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012 Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis, J Urol, 194, 378, 10.1016/j.juro.2015.02.084 Loppenberg, 2017, The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a National Cancer Data Base analysis, Eur Urol, 72, 14, 10.1016/j.eururo.2016.04.031 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Mottet, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 71, 618, 10.1016/j.eururo.2016.08.003 Neal, 2020, Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received, Eur Urol, 77, 320, 10.1016/j.eururo.2019.10.030 Poelaert, 2017, Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective Local Treatment of Metastatic Prostate Cancer (LoMP) trial, Urology, 106, 146, 10.1016/j.urology.2017.02.051 Salembier, 2018, ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer, Radiother Oncol, 127, 49, 10.1016/j.radonc.2018.01.014 Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol, 20, 1248, 10.1200/JCO.2002.20.5.1248 Flanigan, 2004, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J Urol, 171, 1071, 10.1097/01.ju.0000110610.61545.ae Qin, 2012, Tumor cytoreduction results in better response to androgen ablation—a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer, Urol Oncol, 30, 145, 10.1016/j.urolonc.2010.02.010 Psaila, 2009, The metastatic niche: adapting the foreign soil, Nat Rev Cancer, 9, 285, 10.1038/nrc2621 Boeve, 2019, Eur Urol, 75, 410, 10.1016/j.eururo.2018.09.008 Yuh, 2019, Results of phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer, Prostate Int, 7, 102, 10.1016/j.prnil.2018.10.002 Ranasinghe, 2020, The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer, BJU Int, 125, 792, 10.1111/bju.15055 Knipper, 2020, Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H, World J Urol, 38, 1459, 10.1007/s00345-019-02950-0 Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832, 10.1016/j.juro.2014.09.089 Won, 2013, Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer, BJU Int, 112, E250, 10.1111/bju.12169 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7